Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: Implications for cancer therapeutics

Journal of Biological Chemistry

Volumn 288, Issue 1, 2013, Pages 608-618

  Rather, Mohammad Iqbal ^a   Nagashri, Mathighatta N ^a   Swamy, Shivananda S ^b   Gopinath, Kodaganur S ^b   Kumar, Arun ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b Bangalore Institute of Oncology   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPEUTICS; CELL VIABILITY; CO-TRANSFECTIONS; CYCLIND1; DOWN-REGULATION; ECTOPIC EXPRESSIONS; HEK293 CELLS; HETEROZYGOSITY; HUMAN CELL LINES; NUDE MICE; OVER-EXPRESSION; PROMOTER METHYLATION; SQUAMOUS CELL CARCINOMA; THERAPEUTIC INTERVENTION; TUMOR SUPPRESSORS; UP-REGULATION;

ALKYLATION; CELL CULTURE; CELL PROLIFERATION; DISEASES; RNA; TUMORS;

CELL DEATH;

ANTAGOMIR; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 73; MICRORNA 155; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CELL STRAIN HEK293; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; METHYLATION; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR REGRESSION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; BINDING SITES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HELA CELLS; HUMANS; MICE; MICE, NUDE; MICRORNAS; MOUTH NEOPLASMS; NEOPLASM TRANSPLANTATION; NEOPLASMS; PLASMIDS; TUMOR SUPPRESSOR PROTEINS;

MUS MUSCULUS;

EID: 84872058567     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.425736     Document Type: Article

References (46)

1. Shattuck, T. M., Välimäki, S., Obara, T., Gaz, R. D., Clark, O.H., Shoback, D., Wierman, M. E., Tojo, K., Robbins, C. M., Carpten, J. D., Farnebo, L. O., Larsson, C., and Arnold, A. (2003) Somatic and germ line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N. Engl. J. Med. 349, 1722-1729 (Pubitemid 37315009)
2. Aldred, M. J., Talacko, A. A., Savarirayan, R., Murdolo, V., Mills, A. E., Radden, B. G., Alimov, A., Villablanca, A., and Larsson, C. (2006) Dental findings in a family with hyperparathyroidism. Jaw tumour syndrome and a novel HRPT2 gene mutation. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 101, 212-218 (Pubitemid 43163223)
3. Pimenta, F. J., Gontijo Silveira, L.F., Tavares, G. C., Silva, A. C., Perdigão, P. F., Castro, W. H., Gomez, M. V., Teh, B. T., De Marco, L., and Gomez, R. S. (2006) HRPT2 gene alterations in ossifying fibroma of the jaws. Oral. Oncol. 42, 735-739 (Pubitemid 44094240)
4. Carpten, J. D., Robbins, C. M., Villablanca, A., Forsberg, L., Presciuttini, S., Bailey-Wilson, J., Simonds, W. F., Gillanders, E. M., Kennedy, A. M., Chen, J. D., Agarwal, S. K., Sood, R., Jones, M. P., Moses, T. Y., Haven, C., Petillo, D., Leotlela, P. D., Harding, B., Cameron, D., Pannett, A. A., Höög, A., Heath, H., 3rd, James-Newton, L. A., Robinson, B., Zarbo, R. J., Cavaco, B. M., Wassif, W., Perrier, N. D., Rosen, I. B., Kristoffersson, U., Turnpenny, P. D., Farnebo, L. O., Besser, G. M., Jackson, C. E., Morreau, H., Trent, J. M., Thakker, R. V., Marx, S. J., Teh, B. T., Larsson, C., and Hobbs, M. R. (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism. Jaw tumour syndrome. Nat. Genet. 32, 676-680
5. Bradley, K. J., Cavaco, B. M., Bowl, M. R., Harding, B., Young, A., and Thakker, R. V. (2005) Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism. J. Med. Genet. 42, e51
6. Wang, P. F., Tan, M. H., Zhang, C., Morreau, H., and Teh, B. T. (2005) HRPT2, a tumour suppressor gene for hyperparathyroidism-jaw tumour syndrome. Horm. Metab. Res. 37, 380-383 (Pubitemid 41008773)
7. Krogan, N. J., Dover, J., Wood, A., Schneider, J., Heidt, J., Boateng, M. A., Dean, K., Ryan, O. W., Golshani, A., Johnston, M., Greenblatt, J. F., and Shilatifard, A. (2003) The Paf1 complex is required for histone H3methylation by COMPASS and Dot1p. Linking transcriptional elongation to histone methylation. Mol. Cell 11, 721-729 (Pubitemid 36385125)
8. Wood, A., Krogan, N. J., Dover, J., Schneider, J., Heidt, J., Boateng, M. A., Dean, K., Golshani, A., Zhang, Y., Greenblatt, J. F., Johnston, M., and Shilatifard, A. (2003) Bre1, an E3 ubiquitin ligase required for recruitment and substrate selection of Rad6 at a promoter. Mol. Cell 11, 267-274 (Pubitemid 36126607)
9. Rozenblatt-Rosen, O., Hughes, C. M., Nannepaga, S. J., Shanmugam, K. S., Copeland, T. D., Guszczynski, T., Resau, J. H., and Meyerson, M. (2005) The parafibromin tumour suppressor protein is part of a human Paf1 complex. Mol. Cell. Biol. 25, 612-620 (Pubitemid 40096583)
10. Yart, A., Gstaiger, M., Wirbelauer, C., Pecnik, M., Anastasiou, D., Hess, D., and Krek, W. (2005) The HRPT2 tumour suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol. Cell. Biol. 25, 5052-5060 (Pubitemid 40781105)
11. Zhang, C., Kong, D., Tan, M. H., Pappas, D. L., Jr., Wang, P. F., Chen, J., Farber, L., Zhang, N., Koo, H. M., Weinreich, M., Williams, B. O., and Teh, B. T. (2006) Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochem. Biophys. Res. Commun. 350, 17-24 (Pubitemid 44466569)
12. James, R. G., Biechele, T. L., Conrad, W. H., Camp, N. D., Fass, D. M., Major, M. B., Sommer, K., Yi, X., Roberts, B. S., Cleary, M. A., Arthur, W. T., MacCoss, M., Rawlings, D. J., Haggarty, S. J., and Moon, R. T. (2009) Bruton's tyrosine kinase revealed as a negative regulator of Wnt-β-catenin signaling. Sci. Signal. 2, ra25
13. Cetani, F., Pardi, E., Borsari, S., Viacava, P., Dipollina, G., Cianferotti, L., Ambrogini, E., Gazzerro, E., Colussi, G., Berti, P., Miccoli, P., Pinchera, A., and Marcocci, C. (2004) Genetic analyses of the HRPT2 gene in primary hyperparathyroidism. Germline and somatic mutations in familial and sporadic parathyroid tumors. J. Clin. Endocrinol. Metab. 89, 5583-5591 (Pubitemid 39518444)
14. Hewitt, K. M., Sharma, P. K., Samowitz, W., and Hobbs, M. (2007) Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. Ann. Otol. Rhinol. Laryngol. 116, 928-933 (Pubitemid 350308793)
15. Hahn, M. A., Howell, V. M., Gill, A. J., Clarkson, A., Weaire-Buchanan, G., Robinson, B., B., Delbridge, L., Gimm, O., Schmitt, W. D., Teh, B. T., and Marsh, D. J. (2010) CDC73/HRPT2 CpG island hypermethylation and mutation of 5′-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocr. Relat. Cancer 17, 273-282
16. Mehrotra, R., and Yadav, S. (2006) Oral squamous cell carcinoma. Etiology, pathogenesis, and prognostic value of genomic alterations. Indian J. Cancer 43, 60-66 (Pubitemid 43988304)
17. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. (1999) Cancer statistics. CA Cancer J. Clin. 49, 8-31
18. Wu, S., Lin, Y., Xu, D., Chen, J., Shu, M., Zhou, Y., Zhu, W., Su, X., Zhou, Y., Qiu, P., and Yan, G. (2012) MiR-135a functions as a selective killer of malignant glioma. Oncogene 31, 3866-3874
19. Bartel, D. P. (2004) MicroRNAs. Genomics, biogenesis, mechanism, and function. Cell 116, 281-297
20. Zhang, W., Dahlberg, J. E., and Tam, W. (2007) MicroRNAs in tumorigenesis. Am. J. Pathol. 171, 728-738
21. Sobin, L. H., and Fleming, I. D. (1997) TNM classification of malignant tumors, fifth edition. Union Internationale Centre le Cancer and the American Joint Committee on Cancer. Cancer 80, 1803-1804
22. Vaz, C., Ahmad, H. M., Sharma, P., Gupta, R., Kumar, L., Kulshreshtha, R., and Bhattacharya, A. (2010) Analysis of microRNA transcriptome by deep sequencing of small RNA libraries of peripheral blood. BMC Genomics 11, 288
23. Kuhn, D. E., Martin, M. M., Feldman, D. S., Terry, A. V. Jr., Nuovo, G. J., and Elton, T. S. (2008) Experimental validation of miRNA targets. Methods 44, 47-54 (Pubitemid 350297983)
24. Eis, P. S., Tam, W., Sun, L., Chadburn, A., Li, Z., Gomez, M. F., Lund, E., and Dahlberg, J. E. (2005) Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. U.S.A. 102, 3627-3632 (Pubitemid 40354662)
25. Sharbati-Tehrani, S., Kutz-Lohroff, B., Bergbauer, R., Scholven, J., and Einspanier, R. (2008) miR-Q. A novel quantitative RT-PCR approach for the expression profiling of small RNA molecules such as miRNAs in a complex sample. BMC Mol. Biol. 9, 34
26. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25, 402-408 (Pubitemid 34164012)
27. Chakraborty, S., Mohiyuddin, S. M., Gopinath, K. S., and Kumar, A. (2008) Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer 8, 163
28. Jiang, L., Dai, Y., Liu, X., Wang, C., Wang, A., Chen, Z., Heidbreder, C. E., Kolokythas, A., and Zhou, X. (2011) Identification and experimental validation of G protein α inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma. Hum. Genet. 129, 189-197
29. Mignone, F., Gissi, C., Liuni, S., and Pesole, G. (2002) Untranslated regions of mRNAs. Genome Biology 3, S0004
30. Daskalova, E., Baev, V., Rusinov, V., and Minkov, I. (2006) 3′-UTR-located Alu elements. Donors of potential miRNA target sites and mediators of network miRNA-based regulatory interactions. Evol. Bioinform. Online 2, 103-120
31. van den Berg, A., Kroesen, B. J., Kooistra, K., de Jong, D., Briggs, J., Blokzijl, T., Jacobs, S., Kluiver, J., Diepstra, A., Maggio, E., and Poppema, S. (2003) High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Genes Chromosomes Cancer 37, 20-28 (Pubitemid 36417918)
32. Kluiver, J., Poppema, S., de Jong, D., Blokzijl, T., Harms, G., Jacobs, S., Kroesen, B. J., and van den Berg, A. (2005) BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J. Pathol. 207, 243-249 (Pubitemid 41404155)
33. Costinean, S., Zanesi, N., Pekarsky, Y., Tili, E., Volinia, S., Heerema, N., and Croce, C. M. (2006) Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E (mu)-miR155 transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 103, 7024-7029
34. O'Connell, R. M., Rao, D. S., Chaudhuri, A. A., Boldin, M. P., Taganov, K. D., Nicoll, J., Paquette, R. L., and Baltimore, D. (2008) Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J. Exp. Med. 205, 585-594 (Pubitemid 351439306)
35. Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., Ménard, S., Palazzo, J. P., Rosenberg, A., Musiani, P., Volinia, S., Nenci, I., Calin, G. A., Querzoli, P., Negrini, M., and Croce, C. M. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65, 7065-7070 (Pubitemid 41161233)
36. Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., Prueitt, R. L., Yanaihara, N., Lanza, G., Scarpa, A., Vecchione, A., Negrini, M., Harris, C. C., and Croce C. M. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103, 2257-2261 (Pubitemid 43271657)
37. Nikiforova, M. N., Tseng, G. C., Steward, D., Diorio, D., and Nikiforov, Y. E. (2008) Micro-RNA expression profiling of thyroid tumors. Biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 93, 1600-1608 (Pubitemid 351656494)
38. Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., Calin, G. A., Liu, C. G., Croce, C. M., and Harris, C. C. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9, 189-198 (Pubitemid 43357945)
39. Xiqiang, L., Zugen, C., Jinsheng, Y., James, X., and Xiaofeng, Z. (2009) MicroRNA profiling and head and neck cancer. Comp. Funct. Genomics, 11 pp.
40. Esquela-Kerscher, A., and Slack, F. J. (2006) Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259-269
41. Kent, O. A., and Mendell, J. T. (2006) A small piece in the cancer puzzle. Micro-RNAs as tumor suppressors and oncogenes. Oncogene 25, 6188-6196 (Pubitemid 44527849)
42. Gironella, M., Seux, M., Xie, M. J., Cano, C., Tomasini, R., Gommeaux, J., Garcia, S., Nowak, J., Yeung, M. L., Jeang, K. T., Chaix, A., Fazli, L., Motoo, Y., Wang, Q., Rocchi, P., Russo, A., Gleave, M., Dagorn, J. C., Iovanna, J. L., Carrier, A., Pébusque, M. J., and Dusetti, N. J. (2007) Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155 and its restoration inhibits pancreatic tumor development. Proc. Natl. Acad. Sci. U.S.A. 104, 16170-16175 (Pubitemid 350099380)
43. Kong, W., Yang, H., He, L., Zhao, J. J., Coppola, D., Dalton, W. S., and Cheng, J. Q. (2008) MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 28, 6773-6784
44. Costinean, S., Sandhu, S. K., Pedersen, I. M., Tili, E., Trotta, R., Perrotti, D., Ciarlariello, D., Neviani, P., Harb, J., Kauffman, L. R., Shidham, A., and Croce, C. M. (2009) Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eμ-MiR-155 transgenic mice. Blood 114, 1374-1382
45. Zheng, L., Xu, C. C., Chen, W. D., Shen, W. L., Ruan, C. C., Zhu, L. M., Zhu, D. L., and Gao, P. J. (2010) MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts. Biochem. Biophys. Res. Commun. 400, 483-488
46. Greither, T., Grochola, L. F., Udelnow, A., Lautenschläger, C., Würl, P., and Taubert, H. (2010) Elevated expression of microRNAs 155, 203, 210, and 222 in pancreatic tumors associates with poorer survival. Int. J. Cancer 126, 73-80